Margaret Krawiec

12/3/2021  /  Antitrust Investigations , Antitrust Provisions , Competition , Criminal Antitrust Litigation , Criminal Investigations , Enforcement Actions , Enforcement Priorities , Federal Trade Commission (FTC) , Merger Agreements , Merger Controls , Policy Statement

5/5/2021  /  Antitrust Investigations , Biden Administration , Climate Change , Congressional Committees , Congressional Investigations & Hearings , Environmental Policies , Federal Trade Commission (FTC) , Infrastructure

1/28/2021  /  Antitrust Investigations , Big Tech , Congressional Investigations & Hearings , Department of Justice (DOJ) , Drug Pricing , Enforcement Actions , Environmental Protection Agency (EPA) , Environmental Violations , Regulatory Agenda

1/30/2020  /  Acquisitions , Administrative Procedure Act , Anti-Discrimination Policies , Anti-Harassment Policies , Anti-Kickback Statute , Antitrust Investigations , Appeals , Arbitration Awards , Attorney General , Backstop Agreements , BEPS , BitLicense , Blockchain , Board of Directors , Bonds , Capital Markets , CFIUS , CFTC , Chapter 11 , Claim Preclusion , Class Action , Commercial Bankruptcy , Common Stock , Congressional Investigations & Hearings , Congressional Subpoenas , Consumer Financial Protection Bureau (CFPB) , Cooperation Agreement , Copyright , Corporate Governance , Corporate Restructuring , Corporate Social Responsibility , Corporate Taxes , Corwin Doctrine , Covenant Lite Deals , Creditors , Cross-Border Transactions , DACA , DE Supreme Court , Debt Financing , Debtors , Department of Justice (DOJ) , Dischargeable Debts , Disgorgement , Disparate Impact , Dodd-Frank , Down Rounds , Drug Pricing , EBITDA , Employee Retirement Income Security Act (ERISA) , Employer Liability Issues , Employment Discrimination , Enforcement Actions , Enforcement of Foreign Judgments , Enterprise Act 2002 , Environmental Social & Governance (ESG) , EU , Fair Housing Act (FHA) , Federal Trade Commission (FTC) , FinTech , FIRRMA , Foreign Acquisitions , Foreign Investment , Foreign Issuers , FRCP 23 , General Data Protection Regulation (GDPR) , General Elections , GILTI tax , High-Yield Markets , Hong Kong , Hong Kong Stock Exchange , Individual Accountability , Initial Public Offering (IPO) , Intellectual Property Litigation , Intercreditor Agreements , International Arbitration , International Litigation , IRS , Issue Preclusion , Japan , Joint Venture , Legislative Agendas , Life Sciences , Listing Rules , Litigation Strategies , Make-Whole Premium , Mergers , MFW , Multinationals , National Security , PCAOB , Pharmaceutical Industry , Political Parties , Preferred Shares , Private Offerings , Privately Held Corporations , Proxy Advisory Firms , Publicly-Traded Companies , Refinancing , Regulatory Agenda , Reporting Requirements , SCOTUS , Securities and Exchange Commission (SEC) , Securities Litigation , Separation of Powers , Shareholder Activism , Shareholder Proposals , Shareholders , Split of Authority , State Labor Laws , Stock Drop Litigation , Tax Cuts and Jobs Act , Tax Litigation , Technology Sector , Third-Party Release Agrements , Transparency , UK , UK Brexit , Valuation , White Collar Crimes

1/28/2020  /  Acquisitions , Antitrust Investigations , Congressional Investigations & Hearings , Congressional Oversight , Congressional Subpoenas , Constitutional Challenges , Corporate Counsel , Cryptocurrency , Data Breach , Healthcare Facilities , Impeachment , Legislative Agendas , PFAS , Pharmaceutical Industry , Political Parties , Prescription Drugs , Private Equity Firms , Private Sector , Residential Real Estate Market , Retail Market , Subpoenas , Trump Administration